Fujifilm To Invest $55-Million To Expand Gene-Therapy Development CapabilitiesBy
Fujifilm Diosynth Biotechnologies (FDB), a contract biologics manufacturer, has announced the expansion of its gene-therapy services with the addition of dedicated process and analytical development laboratories. As part of a capital investment of approximately YEN 13 billion ($120 million) in the gene-therapy field by Fujifilm, FDB is investing approximately $55 million to establish a new Gene Therapy Innovation Center adjacent to FDB’s existing cGMP gene-therapy manufacturing facility in College Station, Texas.
The Gene Therapy Innovation Center will be approximately 60,000 square feet and will house upstream, downstream, and analytical development technologies. The company says the new facility is expected to triple its gene-therapy development capabilities and add approximately 100 jobs to its Texas campus. The facility is expected to be operational in the fall of 2021.